Parity for Non-Opioid Pain Management Drugs
Sponsored By: Barbara Kirkmeyer (Republican), Judy Amabile (Democratic), Kyle Brown (Democratic), Rick Taggart (Republican)
Third Reading
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
No Economic Impacts Identified for this Bill
Sponsors & Cosponsors
Sponsors
Barbara Kirkmeyer
Republican • Senate
Judy Amabile
Democratic • Senate
Kyle Brown
Democratic • House
Rick Taggart
Republican • House
Cosponsors
Byron Pelton
Republican • Senate
James Coleman
Democratic • Senate
Katie Wallace
Democratic • Senate
Lisa Cutter
Democratic • Senate
Lisa Frizell
Republican • Senate
Marc Catlin
Republican • Senate
Scott Bright
Republican • Senate
Roll Call Votes
No roll call votes available for this bill.
Actions Timeline
House Committee on Health & Human Services Refer Unamended to Appropriations
4/22/2026HouseSenate Third Reading Passed - No Amendments
4/20/2026SenateIntroduced In House - Assigned to Health & Human Services
4/20/2026HouseSenate Committee on Appropriations Refer Unamended to Senate Committee of the Whole
4/17/2026SenateSenate Second Reading Special Order - Passed with Amendments - Committee
4/17/2026SenateSenate Committee on Health & Human Services Refer Amended to Appropriations
4/8/2026SenateSenate Committee on Health & Human Services Witness Testimony and/or Committee Discussion Only
4/2/2026SenateIntroduced In Senate - Assigned to Health & Human Services
1/14/2026Senate
Bill Text
Engrossed
Introduced
PA1
Reengrossed
Related Bills
HB26-1133 — Traveling Animal Protection Act Environmental Education Program
SB26-021 — Clean Fleet Enterprise Replace Aging Diesel Trucks
SB26-110 — Revised Public Assistance Final Disposition Expense Terms
SB26-126 — Licensure for Experienced Out-of-State Teachers
SB26-031 — Use of Prescription Product with Controlled Substance
SB26-077 — Epilepsy-Related Mortality Awareness